<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874246</url>
  </required_header>
  <id_info>
    <org_study_id>2011-107-1174</org_study_id>
    <nct_id>NCT04874246</nct_id>
  </id_info>
  <brief_title>Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy</brief_title>
  <acronym>VALENTINE</acronym>
  <official_title>Diluted VAsopressin During Robot-assisted Laparoscopic myomEctomy for dimiNishing Blood Loss According To the Dilution Concentration of Normal salINE: a Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of the concentration of vasopressin, which&#xD;
      is used as a method for reducing blood loss in robot-assisted laparoscopic myomectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to compare the effect of the concentration of vasopressin, which is used as a&#xD;
      method for reducing blood loss in robot-assisted laparoscopic myomectomy. We would like to&#xD;
      evaluate the feasibility and validity of this study for future Phase III randomized clinical&#xD;
      trials through this preliminary randomized assignment study.&#xD;
&#xD;
      Uterine fibroids are the most common tumors in women, and uterine myomectomy, which is&#xD;
      performed as a treatment for them, is basically a high risk of bleeding and blood&#xD;
      transfusion. A common method to reduce intraoperative bleeding is to inject diluted&#xD;
      vasopressin into the subserosal areas of the fibroids. However, no proper level of&#xD;
      vasopressin dilution has been determined so far, so we want to determine an effective&#xD;
      dilution concentration of vasopressin that can minimize side effects through this clinical&#xD;
      trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated blood loss (EBL) during operation</measure>
    <time_frame>during operation</time_frame>
    <description>The volume of blood loss will be estimated by using simple visual assessment technique referring to irrigation bottle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Post-op 1 day</time_frame>
    <description>Change of serum hemoglobin from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Post-op 1 day</time_frame>
    <description>Change of serum hematocrit from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation running time</measure>
    <time_frame>during operation</time_frame>
    <description>Time from anesthesia start to delivery of patient to recovery room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion</measure>
    <time_frame>Post-op 2 days</time_frame>
    <description>Whether patients are transfused during admission period Number of units transfused red blood cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of fluid injected during operation</measure>
    <time_frame>during operation</time_frame>
    <description>The amount of fluid injected during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization period</measure>
    <time_frame>Within post-op 1 week</time_frame>
    <description>Days from admission day to discharge day</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Uterine Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Diluted Vasopressin Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 50 ml of normal saline to make a total of 100 ml) was injected before uterine serosal incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diluted Vasopressin Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 200 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diluted Vasopressin Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 400 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.</description>
    <arm_group_label>Diluted Vasopressin Group 1</arm_group_label>
    <arm_group_label>Diluted Vasopressin Group 2</arm_group_label>
    <arm_group_label>Diluted Vasopressin Group 3</arm_group_label>
    <other_name>Vasopressin 20U</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Age: 19-60 year-old women&#xD;
&#xD;
          -  Plan of myomectomy for uterine leiomyomas&#xD;
&#xD;
          -  Leiomyoma Subclassification System 2-7 (robot-assisted laparoscopic myomectomy is&#xD;
             possible)&#xD;
&#xD;
          -  American Society of Anesthesiologists Physical Status classification 1 or 2&#xD;
&#xD;
          -  A person who understands the contents of the clinical trial, is cooperative with the&#xD;
             trial, and is judged to be able to participate until the end of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  A single diameter of uterine leiomyoma is greater than 12 cm or more or multiple&#xD;
             leiomyomas with more than five&#xD;
&#xD;
          -  Suspicious disease of uterine malignancy&#xD;
&#xD;
          -  Patient with has a history of pelvic surgery (cesarean section, myomectomy, etc.) and&#xD;
             is expected to have severe pelvic adhesion&#xD;
&#xD;
          -  A person who is hypersensitive or contraindicated to vasopressin&#xD;
&#xD;
          -  A person who is hypersensitive or contraindicated to tranexamic acid&#xD;
&#xD;
          -  Considered as inappropriate by the researcher's judgment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Seung Kim, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee Seung Kim, MD/PhD</last_name>
    <phone>82-2-2072-4863</phone>
    <email>bboddi0311@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun Ji Lee, MD</last_name>
    <phone>82-2-2072-3629</phone>
    <email>happyeunji0103@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Eun Ji Lee, MD</last_name>
      <phone>82-2-2072-3629</phone>
      <email>happyeunji0103@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hee Seung Kim, MD/PhD</last_name>
      <phone>82-2-2072-4863</phone>
      <email>bboddi0311@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 2, 2021</study_first_submitted>
  <study_first_submitted_qc>May 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee Seung Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Leiomyoma</keyword>
  <keyword>Uterine fibroid</keyword>
  <keyword>Uterine Myomectomy</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Vasopressin</keyword>
  <keyword>Dilution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

